Vigil Neuroscience (VIGL)
(Delayed Data from NSDQ)
$8.05 USD
0.00 (0.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $8.06 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VIGL 8.05 0.00(0.00%)
Will VIGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIGL
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?
VIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
Other News for VIGL
Catalyst Watch: Palantir earnings, Firefly Aerospace IPO, OPEC+, and the Fed's SLOOS report
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Tesla, Alphabet Set To Report Earnings As Investors Watch Out For Jobless Claims And Durable Goods Orders
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact